Search

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

An update on inherited retinal disorders (part 2): Approaches to therapy for IRDs

Part 1 of this topic can be found here There are currently no proven cures for inherited retinal disease (IRD). However, multiple avenues of research are being investigated to better understand disease mechanisms and trial potential therapies that may slow...

Surgical treatment of high myopia

Although several excellent modalities are available for correcting high myopia, the surgical treatment of this condition remains one of the biggest challenges for refractive surgeons; this group of patients is often very dependent on contact lenses. If these patients become...

The role of inflammation in the pathophysiology of DMO

Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...

Designing ophthalmology services Part 3: How do we address the queues post‑COVID-19?

Part 1 of this series available herePart 2 of this series available here There is going to be enormous demand on ophthalmology services as they start to welcome patients back. The authors explain how modelling can help make the most...

Designing ophthalmology services - Part 1: How do we address the queues in a clinic?

This first of a three-part series shows how systems engineering can be used to correctly diagnose and address the causes of delays in a clinic. The second article, which will be featured in the April/May 2020 issue, describes how to...